Abilify approved for bipolar adolescents
Executive Summary
Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify (aripiprazole) wins approval for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in patients 10 to 17 years old, the firms announce Feb. 29. The approval provides clinicians with expanded treatment options for pediatric patients with bipolar I disorder, following approval in August for Johnson & Johnson's Risperdal (risperidone) for that age group. Last November, Bristol/Otsuka's dopamine partial agonist, which was already indicated for treatment of bipolar I disorder and schizophrenia, won approval for treatment of schizophrenia in adolescents (1"The Pink Sheet" Feb. 4, 2008, p. 10)
Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify (aripiprazole) wins approval for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in patients 10 to 17 years old, the firms announce Feb. 29. The approval provides clinicians with expanded treatment options for pediatric patients with bipolar I disorder, following approval in August for Johnson & Johnson's Risperdal (risperidone) for that age group. Last November, Bristol/Otsuka's dopamine partial agonist, which was already indicated for treatment of bipolar I disorder and schizophrenia, won approval for treatment of schizophrenia in adolescents (1 (Also see "Bristol Readies Abilify Sales Force For Major Depressive Disorder Push" - Pink Sheet, 4 Feb, 2008.), p. 10). |